GLP-1 Agonist Linked to Dysphoria and Aggression in Depressed Patient

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as tirzepatide, have rapidly emerged as a highly promising therapeutic option for patients seeking significant weight loss and improved metabolic health. While their efficacy in managing obesity and type 2 diabetes is well-established, there remains a significant knowledge gap regarding the full spectrum of their potential psychiatric side effects. This detailed case report specifically addresses the potential for GLP-1 RAs to induce profound mood disturbances, including dysphoria and aggression, in susceptible individuals with pre-existing psychiatric vulnerabilities.

Following the initiation of tirzepatide, the patient experienced a marked and concerning increase in impulsivity, severe dysphoria (described as a profound state of unease, dissatisfaction, and general unhappiness), and episodes of aggression. These adverse psychiatric symptoms were clearly observed and documented after the patient began the medication. > Crucially, all reported symptoms of increased impulsivity, dysphoria, and aggression resolved completely and spontaneously within a short period following the cessation of tirzepatide, demonstrating a strong temporal and causal relationship. This direct link between drug initiation, symptom onset, and symptom resolution upon discontinuation provides compelling evidence for the GLP-1 RA as the precipitating factor for the observed mood disturbances in this specific patient.